NeuroGenomeX, Inc.

Company News

NeuroGenomeX, Inc. Announces Raising $1.024 Million

January 2011, Madison, WI -- NeuroGenomeX, Inc. announced today that it had completed a $1.024 million funding round to further develop its lead compound for the treatment of intractable epilepsy. 2-deoxy-D-glucose (2DG) is a novel small molecule therapeutic that acts by a completely novel mechanism of action to suppress epileptic seizures.

This most current funding round raises the total funds raised by NeuroGenomeX to $2.416M. The previous funding rounds were completed in 2001 & 2005.

‹- Back